Arthneeti
Latest: Neuland Labs. Q1 FY27 results →All Q2 FY26 results →
NL

Neuland Labs.

Q2 FY26

Neuland Laboratories Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Price₹19,675
Market cap₹25.2K Cr
P/E50.7
Updated16 Oct 2026
Read4 min read

The short version

FY26 is expected to be a year of strong growth compared to FY24, with momentum continuing through the year. FY26 is expected to be a year of strong growth based on the FY24 base, indicating positive earnings momentum.

From Neuland Labs.'s Q2 FY26 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

  • FY26 is expected to be a year of strong growth compared to FY24, with momentum continuing through the year.
  • Commercialization of new molecules is anticipated, including one recently validated product expected to start shipments soon.
  • A strong pipeline of new projects entered in the last 6-8 months is under process development and scale-up, expected to result in increased business over the next 12-18 months.
  • GDS business growth driven by products like Ezetimibe and Mirtazapine; specialty segment expected to grow slowly over the next financial year.
  • Investment in a large-scale peptide facility aligns with future growth opportunities in complex molecules, including peptides and oligonucleotides.

2 more points from Neuland Labs.'s call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Neuland Labs. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Neuland Laboratories is investing significantly in building a large-scale peptide manufacturing facility.
  • The initial investment for Peptide Module-1 and civil work for Module-2 is approximately Rs. 250-280 crores.
  • Total capital expenditure to fully build out the large-scale peptide production suite is projected to exceed Rs. 1000 crores.
  • The company plans to construct Modules 3 and 4 later based on customer requirements.
  • CAPEX also includes investments in modernizing R&D setups with advanced equipment to enhance process development efficiency.
  • Ongoing investments include new production units like Unit-III, which was recently commissioned with a Rs. 128 crore investment.

2 more points from Neuland Labs.'s call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Neuland Labs. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Neuland does not have direct confirmed visibility of commercial projects for the next 12 to 18 months, except for one project "around the corner."
  • There could be late-stage opportunities in conversations but nothing definitive yet.
  • The company sees good traction with a range of customers across geographies, especially in peptides and specialty molecules.
  • New business and increased share from existing customers are expected over the next 12 to 18 months.
  • Investment in peptide facilities is on track, supporting long-term growth and attracting exciting customers.

2 more points from Neuland Labs.'s call on order book

Create a free account to keep reading this call

Neuland Labs. — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹776 Cr, net profit ₹213 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Neuland Laboratories Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare Ltd (Q2 FY26)

    For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

  • Infinium Pharmachem Ltd (Q2 FY26)

    Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium

  • Wanbury (Q2 FY26)

    Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Balaxi Pharmaceuticals Ltd (Q2 FY26)

    Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Neuland Labs. and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Neuland Labs. Q2 FY26 results?

FY26 is expected to be a year of strong growth compared to FY24, with momentum continuing through the year. FY26 is expected to be a year of strong growth based on the FY24 base, indicating positive earnings momentum.

What is Neuland Labs. share price analysis?

Neuland Labs. currently shows a neutral. The stock trades at a P/E of 50.7 with a market cap of ₹25,243 Cr. Investors should review the full earnings analysis for detailed insights.

Is Neuland Labs. planning capital expenditure?

Neuland Laboratories is investing significantly in building a large-scale peptide manufacturing facility. - The initial investment for Peptide Module-1 and civil work for Module-2 is approximately Rs.

Keep Neuland Labs. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.